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CLINICAL INVESTIGATIONS 
Prevention of ventricular fibrillation by bretylium 
in a conscious canine model of sudden 
coronary death 
In anesthetized dogs, a silver wire electrode was inserted into the lumen of the circumflex 
coronary artery (LCX) and myocardial infarction was produced by a temporary gO-minute 
occlusion of the left anterior descending coronary artery (LAD) followed by reperfusion. Four 
days later while in the ambulatory state, a 150 PA current was applied to the intimal surface of 
the LCX of saline (n = 10) and bretylium (n = 10) treated animals. lntimal injury and coronary 
thrombosis produced ST segment changes at 138 + 39 minutes (X f SEM), followed by 
premature ventricular beats (at 142 f 37 minutes), ventricular tachycardia (at 156 k 49 minutes), 
and ventricular fibrillation (at 163 + 51 minutes) in g of 10 saline-treated animals. In 
bretylium-treated animals, ST segment changes appeared at 128 f 35 minutes, with six animals 
surviving for 24 hours (p < 0.03 vs saline). LAD infarction was present in both saline 
(14.1 f 2.3%) and bretylium (15.1 + 2.1% of left ventricle) treated animals with only 
bretylium-treated animals developing LCX infarcts (16.1 rt 2.1%). Bretylium prevents ventricular 
fibrillation (VF) resulting from ischemia at a site distant to prior myocardial infarction in the 
conscious dog and deserves further attention as a potential antifibrillatory agent for prevention 
of sudden coronary death in man. (AM HEART J 105711, 1983.) 
Kurt Holland, B.S., Eugene Patterson, Ph.D., and Benedict R. Lucchesi, Ph.D., M.D. 
Ann Arbor, Mich. 
The high incidence of sudden coronary death in the 
United States and the failure of current antiarrhyth- 
mic drug therapy to prevent total events suggests a 
need to develop new antifibrillatory drugs capable of 
preventing unexpected death due to ventricular 
fibrillation. Bretylium tosylate, a quaternary ammo- 
nium antiarrhythmic agent, possesses antifibrilla- 
tory properties which may make it a suitable agent 
for the prevention of ventricular fibrillation in 
humans. Bretylium increases the electrical thresh- 
old for induction of ventricular fibrillation in the 
dog under normal physiologic conditions’s2 and dur- 
ing acute myocardial ischemia.3p4 Bretylium also 
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protects against ventricular fibrillation occurring 
from coronary artery occlusion and reperfusion.2 
While it is not possible to extrapolate these results 
readily to humans, bretylium has been shown to be 
effective in suppressing ventricular tachycardia and 
ventricular fibrillation occurring after cardiac sur- 
gery or during acute myocardial infarction.5-7 Brety- 
hum can also suppress ventricular tachycardia pro- 
duced in conscious dogs by programmed electrical 
stimulation during the convalescent phase of myo- 
cardial infarction.svg Although these studies might 
suggest an antifibrillatory action of bretylium, little 
is known about the ability of the drug to prevent the 
spontaneous development of ventricular fibrillation 
in the presence of myocardial ischemic injury-a 
situation more analogous to the clinical event of 
sudden coronary death. 
Recently we described a conscious canine model 
of sudden coronary death which is marked by the 
spontaneous development of ventricular fibrillation, 
a result of acute myocardial ischemia in the presence 
of previous myocardial infarction.” In the present 
study we examined the ability of bretylium to 
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prevent ventricular fibrillation in this conscious 
canine model of sudden coronary death. The results 
of this investigation provide evidence that the qua- 
ternary ammonium drug, bretylium, has an ability 
to prevent the development of ventricular fibrilla- 
tion in response to an acute ischemic event at a site 
remote from a previous infarct. 
METHODS 
Surgical preparation. Male mongrel dogs weighing 
between 14 and 22 kg were anesthetized with intravenous 
sodium pentobarbital (30 mg/kg). A cuffed endotracheal 
tube was inserted and the animals were ventilated with 
room air using a Harvard respirator. Under aseptic 
conditions, a cannula was inserted into the left external 
jugular vein and exteriorized at the back of the neck. A left 
thoracotomy was performed in the fourth intercostal 
space and the heart was suspended in a pericardial cradle. 
Using blunt dissection, the left anterior descending coro- 
nary artery was isolated free from surrounding myocardi- 
urn at the tip of the left atria1 appendage. Coronary artery 
flow was measured with an electromagnetic flow probe. A 
hypodermic needle with a blunted end was placed parallel 
to the coronary artery and a suture was passed around 
both the coronary artery and the needle. The suture was 
tied securely and the needle was withdrawn, thereby 
producing a critical stenosis. The needle size was adjusted 
so that the maximal hyperemic response to a lo-second 
occlusion of the coronary artery was reduced by 60% or 
more without reducing resting coronary artery flow. The 
left anterior descending coronary artery was then oc- 
cluded using a snare formed from a loop of silicone rubber 
tubing passed through a blunt-ended polyethylene tube. 
After 90 minutes, the occlusive snare was removed and 
flow was restored through the stenosed artery. 
Programmed electrical stimulation. Programmed elec- 
trical stimulation was performed while the animal was 
conscious and was resting comfortably in a sling. Prema- 
ture stimuli (4 msec duration, two times diastolic thresh- 
old) were introduced into the interventricular septum 
using a Grass S-88 stimulator and SW-5 stimulus isola- 
t,ion unit. ,4 Tektronix 565 oscilloscope with type 3A8 
operational amplifier was used to trigger the ventricular 
stimulus from the R wave of t,he lead 11 ECG. 
The programmed electrical stimulation procedure used 
is summarized below. (I) Single premature ventricular 
stimuli (S,) at two times diastolic threshold were intro- 
duced during normal sinus rhythm at decreasing 10 msec 
intervals from 350 msec until ventricular refractoriness 
developed. (2) Double premature ventricular stimuli (S, 
S:,) at two times diastolic threshold were introduced 
during normal sinus rhythm at decreasing 10 msec inter- 
vals for S, stimuli from 350 msec until ventricular refrac- 
toriness developed with S,-S:, intervals of 200. 180, 170, 
160, 150, 140, 13.5, and 130 msec. (3) Triple premature 
ventricular stimuli (S.!, S,, Y,) at t.wo times diastolic 
threshold were introduced during normal sinus rhythm at 
decreasing 10 msec intervals for S, stiumuli from 350 msec 
until ventricular refractoriness developed with S,-S; and 
S,& intervals as stated above. i4) Intermittent ventricu- 
lar pacing (three to eight beats, two times diastolic 
threshold) at, constant rates of’ 250, 330, and ,160 bpm was 
applied. 
The proximal 5 mm of the left circumflex coronary 
artery was isolated and the tip of a 30-gauge insulated 
silver wire was inserted through the wall into the vessel 
lumen. A bipolar electrode (25-gauge insulated stainless 
steel wire, 4 to 5 mm in length, 2 mm apart) was placed 
into the interventricular septum adjacent to the right 
ventricular outflow tract and silver electrodes were 
implanted subcutaneously for monitoring of a lead II 
ECG. The chest was closed in layers and the animals 
received intramuscular ampicillin (10 mg/kg). 
Previous studies have shown that this method of pro- 
grammed electrical stimulat.ion fails to produce ventricu- 
lar arrhythmias in sham-operated animals without previ- 
ous myocardial infarction.” Programmed stimulation was 
discontinued when ventricular tachycardia was repro- 
duced in t.riplicate or when the entire stimulation proce- 
dure was completed. The lead II ECG was recorded 
continuously on a Grass model 7 polygraph and was stored 
on magnetic tape. The effective refractory period of 
normal left ventricular myocardium was determined at 
two times diastolic threshold (4 msec duration square 
wave pulse). 
Drug administration. On day three after myocardial 
infarction, normal sinus rhythm had returned and the 
animals were allocated randomly to one of two treatment 
groups in a double-blind fashion. One group received 
intravenous saline (20 ml) every 12 hours for four doses 
and the second group received bretylium tosylate, 10 
mg/kg in 20 ml saline, every 12 hours for four doses. After 
24 hours of treatment (12 hours after the second dose and 
immediately before the third dose), programmed electrical 
stimulation was performed while the animal was conscious 
and resting comfortably in a sling. 
Initiation of current flow to the intimal surface of the 
left circumflex coronary artery. Immediately after drug 
administration (dose 3), an anodal direct current of 150 PA 
was applied to the electrode previously inserted into the 
left circumflex coronary artery. The current source was a 9 
V battery placed in series with a 250 kQ potentiometer. 
The cathode was a silver disc electrode (5 mm diameter) 
previously implanted subcutaneously. Electrical stimula- 
tion of the intimal surface was continued for 12 hours. The 
lead II ECG was transmitted from the conscious ambula- 
tory dog via radiotelemetry and recorded continuously on 
magnetic tape for 12 hours followed by intermittent 
sampling (28 seconds of recording every 15 minutes) for an 
additional 12 hours. 
After administration of the third treatment dose, an Twenty-four hours after initiation of current flow to the 
anodal current of 150 PA was applied to the intimal intimal surface of the left circumflex coronary artery, the 
surface of the left circumflex coronary artery. Twelve 
hours later, the final (fourth) treatment dose was admin 
istered and the anodal current was discontinued. 
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Fig. 1. Ventricular fibrillation in a conscious canine model of sudden coronary death. Programmed 
electrical stimulation (upper left panel) using single premature ventricular stimuli produced nonsus- 
tained ventricular tachycardia on day 4 after anterior myocardial infarction. Normal sinus rhythm 
immediately prior to initiating current flow to the intimal surface of the left circumflex coronary artery is 
shown in the upper left panel. At 150 minutes, ST segment depression becomes apparent (not shown). At 
155 minutes, a ventricular couplet, ventricular tachycardia, and ventricular fibrillation develop. 
surviving animals were killed with an overdose of sodium 
pentobarbital. The heart was removed and sectioned into 
1 cm rings from apex to base, parallel to the atrioventric- 
ular groove. The sections were placed into 0.5% triphenyl- 
tetrazolium chloride in 0.1 M potassium phosphate buffer, 
pH 7.4. Infarct size was determined gravimetrically. The 
left circumflex coronary artery was removed by careful 
dissection and was examined for the presence of thrombo- 
sis. 
Statistics. Differences in survival rates between groups 
were analyzed by the Fisher exact test. Differences 
between groups were determined by a one-way analysis of 
variance. A value of p < 0.05 was selected as the criterion 
for significance. Data are expressed as mean * the stan- 
dard error of the mean @EM). 
RESULTS 
Programmed electrical stimulation. On day 4 after 
myocardial infarction, the presence or absence of 
underlying myocardial electrical instability was 
determined by the use of programmed electrical 
stimulation. In saline-treated animals, programmed 
electrical stimulation produced nonsustained ven- 
tricular tachycardia in six animals and failed to 
produce ventricular tachycardia in four animals. 
Ventricular fibrillation was produced in one dog, 
thereby eliminating this animal from further study. 
In drug-treated animals, programmed stimulation 
performed 12 hours after the second bretylium dose 
failed to produce ventricular tachycardia in nine 
animals and produced nonsustained ventricular 
tachycardia in one animal. This was a significant 
reduction in the incidence of myocardial electrical 
instability in the bretylium-treated group 
(p = 0.027). The left ventricular effective refractory 
period (interventricular septum) in bretylium- 
treated animals (189 i 3 seconds) was significantly 
greater (p < 0.01) than that observed in saline- 
treated animals (153 k 4 seconds). 
Application of current to the intimal surface of the left 
circumflex coronary artery. An anodal current of 150 
PA was applied to the intimal surface of the left 
circumflex coronary artery via a wire previously 
inserted into the arterial lumen. In saline-treated 
animals (n = lo), ST segment elevation or depres- 
sion in excess of 0.3 mV developed at 138 +- 39 
minutes. Ventricular fibrillation occurred in 9 of 10 
animals at 162 + 39 minutes and was preceded by 
the development of premature ventricular beats at 
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Fig. 2. Effect of chronic bretylium therapy (10 mg/kg every 12 hr). Normal sinus rhythm is present 4 
days after anterior myocardial infarction (upper left panel). At 43 minutes, ST segment elevation 
develops (upper right panel). ST segment depression and premature ventricular contractions are present 
at 2 hours, 9 minutes, and at 8 hours (middle panels). At 24 hours, the ECG consists entirely of ventricular 
premature beats (bottom panel). 
142 it_ 37 minutes, with development of ventricular 
tachycardia at 156 -t 49 minutes. Representative 
ECGs from saline-treated animals can be seen in 
Fig. 1. 
In bretylium-treated animals (n = lo), ST seg- 
ment elevation or depression in excess of 0.3 mV 
developed at 128 +- 35 minutes. Ventricular fibrilla- 
tion developed in one animal at 16 hours and in a 
second animal at 9 hours. Two animals died at 42 
minutes and 58 minutes, respectively, after the 
development of bradycardia which led to idioven- 
tricular rhythms and electromechanical dissocia- 
tion. Six animals survived the entire 24-hour proto- 
col. All surviving animals developed posterolateral 
wall infarction and premature ventricular ectopic 
beats (89 ? 5 % of all beats at 24 hours). Ventricular 
tachycardia did not appear in 8 of 10 animals until 
286 +- 37 minutes after the appearance of ST seg- 
ment changes. A representative lead II ECG 
obtained from a bretylium-treated animal is shown 
in Fig. 2. Bretylium treatment significantly 
increased survival when compared to saline treat- 
ment (Fig. 3). 
No significant difference in time to ST segment 
change was observed between the two treatment 
groups. The extent of irreversible ischemic injury 
produced by a go-minute occlusion-reperfusion of 
the left anterior descending coronary artery did not 
differ between saline (14.6 + 2.2 gm, 14.1 rfr 2.3% of 
left ventricle) and bretylium (15.2 -t 2.1 gm, 15.1 + 
2.1% of left ventricle) treated groups. In saline- 
treated animals, irreversible ischemic damage with- 
in the left circumflex coronary artery distribution 
was not observed except in the one animal surviving 
the entire 24-hour protocol. Myocardial infarction 
(16 -t 2% of left ventricular mass) was observed 
within the left circumflex distribution of all eight 
animals of the bretylium-treated group which sur- 
vived 9 or more hours into the experimental proto- 
col. 
Intimal injury and occlusive coronary artery 
thrombi were observed within the left circumflex 
coronary artery in all 13 animals surviving in excess 
of 3 hours after electrical stimulation was initiated. 
Nonocclusive thrombi or an absence of thrombosis 
was observed in six of seven animals dying prior to 3 
hours. Thrombus mass was not different in saline 
(10 +- 4 mg) and bretylium (20 + 6 mg) treated 
groups. 
DISCUSSION 
Animal models. Epidemiologic’z,‘3 and electrophys- 
iologic4.” studies in patients resuscitated from epi- 
sodes of sudden coronary death have revealed the 
presence of coronary artery disease and continuing 
myocardial electrical instability. The search for 
pharmacologic interventions capable of preventing 
sudden coronary death has been hampered primari- 
ly by a lack of suitable animal models. Most animal 
models currently used for the study of antiarrhyth- 
mic drugs poorly simulate the continuous electrical 
instability associated with the development of reen- 
trant ventricular arrhythmias and sudden coronary 
death. Ventricular tachyarrhythmias present 24 to 
72 hours after experimental myocardial infarction 
(the widely used model of Harris”? rarely proceed to 
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ventricular fibrillation. The frequency of ventricular 
premature beats declines over a period of several 
days, not representing chronic myocardial electrical 
instability, with the relative slow rate of ventricular 
tachycardia resulting from enhanced Purkinje fiber 
automaticity rather than from localized reentry of 
myocardial electrical activity.‘? Reentrant ventricu- 
lar arrhythmias produced by coronary artery occlu- 
sion or reperfusion frequently terminate in ventricu- 
lar fibrillation. The arrhythmias also poorly simu- 
late the presence of chronic myocardial electrical 
instability so prevalent in patients resuscitated from 
episodes of sudden coronary death. Recently it has 
been shown that ventricular tachyarrhythmias pro- 
duced in the dog by programmed electrical stimula- 
tion 3 to 14 days after myocardial infarction closely 
resemble those observed in patients rescued from 
out-of-hospital death. These ventricular tachyarr- 
hythmias can be initiated and terminated with 
premature ventricular stimuli.8~s~ 18-22 Induction of 
ventricular tachyarrhythmias is dependent upon 
local fractionation of electrical activity and delayed 
activation of ventricular myocardium. Areas of uni- 
directional block and circuitous delayed activation 
of isolated segments of ventricular myocardium 
have been demonstrated.22 Continuous diastolic 
electrical activity has been recorded from areas 
overlying irreversibly injured ventricular myocardi- 
urn 18*ls providing further support for the existence 
of i reentrant mechanism. More importantly, the 
electrical instability is present over a period of 
weeks and can result in the development of ventric- 
ular fibrillation. 
Programmed electrical stimulation. Despite the 
close similarities in the electrophysiologic and clini- 
cal aspects of programmed electrical stimulation in 
the dog during the subacute phase of myocardial 
infarction and in patients resuscitated from sudden 
coronary death, programmed electrical stimulation 
in the dog differs from the development of sudden 
coronary death in humans in two major aspects. (1) 
ECGs recorded from patients at risk for develop- 
ment of sudden coronary death are marked by a high 
incidence of multiform premature ventricular beats, 
ventricular couplets, and nonsustained ventricular 
tachycardia.23,24 During the convalescent phase of 
experimental myocardial infarction in the dog 3 to 
14 days after myocardial infarction, spontaneous 
development of ventricular arrhythmias is rare. (2) 
Ventricular fibrillation followed by circulatory col- 
lapse, the presumed etiology of sudden coronary 
death, develops spontaneously in humans. In the 
dog, ventricular fibrillation develops only upon 
provocation by the electrical induction of premature 
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Fig. 3. Effect of bretylium upon survival in a canine 
model of sudden coronary death. Cummulative survival 
after time 0 (initiation of current flow to the intimal 
surface of the left circumflex coronary artery) is shown for 
saline- and bretylium-treated animals. At 24 hours, brety- 
lium tosylate (10 mg/kg every 12 hours) significantly 
increased (p < 0.03) survival compared to the saline- 
treated group. 
ventricular beats. The conscious canine model of 
sudden coronary death described here spontaneous- 
ly develops ventricular arrhythmias and ventricular 
fibrillation when acute myocardial ischemia is pro- 
duced in the presence of chronic myocardial electri- 
cal instability resulting from previous myocardial 
infarction; this may provide a model which closely 
simulates the development of ventricular fibrillation 
in humans. Recent work performed in our laborato- 
ry has shown that the increased sensitivity to devel- 
opment of ventricular fibrillation is maintained for 
more than 30 days after myocardial infarction in the 
left anterior descending distribution, with ventricu- 
lar fibrillation developing in seven of seven animals 
subjected to electrical stimulation of the left circum- 
flex coronary artery intimal surface. Although the 
animals studied in this report were examined 4 days 
after myocardial infarction, we believe that compa- 
rable mechanisms may be involved when acute is- 
chemia intercedes at later times. Still, it remains 
difficult to extrapolate these results to humans, 
since the exact triggers or circumstances responsible 
for initiation of ventricular fibrillation in humans 
are unknown. Nevertheless, this study does demon- 
strate the ability of bretylium to prevent the high 
incidence of ventricular fibrillation observed when 
acute ischemia intervenes in the setting of earlier 
myocardial infarction. 
Bretylium electrophysiologic properties. Bretylium 
exerts both direct effects upon cardiac tissue and 
indirect effects mediated via its action upon the 
sympathetic nervous system. Either one or both of 
these actions may be involved in the ability of 
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bretylium to prevent ventricular fibrillation in the 
conscious canine model we have described. The 
direct action of bretylium upon cardiac tissue is to 
increase action potential duration, an effect most 
prominently exhibited in ventricular myocardi- 
um.25s 26 This action was probably responsible for the 
significantly larger effective refractory periods 
observed in the bretylium-treated animals, and may 
be the mechanism by which bretylium prevents the 
induction of ventricular tachyarrhythmias in 
response to programmed electrical stimulation dur- 
ing the recovery phase of experimental myocardial 
infarction.‘*’ 
The acute administration of bretylium releases 
catecholamines from sympathetic nerve terminalsz7 
After uptake into sympathetic nerve terminals, bre- 
tylium inhibits catecholamine release caused by 
sympathetic nervous system stimulation.2v27 The 
release of catecholamines from sympathetic nerve 
terminals can cause hyperpolarization of damaged 
cardiac cell fibers and can improve myocardial con- 
duction 26*27 This action of bretylium has also been 
suggested as a possible mechanism for its antifibril- 
latory action. 26 However, inhibition of norepineph- 
rine release from sympathetic nerve terminals may 
be involved in the ability of bretylium to prevent 
ventricular fibrillation resulting from acute myocar- 
dial ischemia in the presence of prior myocardial 
infarction. Swartz and Stone28 have shown that left 
stellate ganglionectomy lowers the incidence of ven- 
tricular fibrillation produced by a short-term occlu- 
sion-reperfusion of the left circumflex coronary 
artery in the presence of previous myocardial infarc- 
tion. Interruption of sympathetic nerve release of 
norepinephrine in the heart may have prevented 
myocardial electrical instability in our experiments 
and may be a factor in bretylium’s antifibrillatory 
action. 
Conclusions. Recent advances in our knowledge 
concerning risk factors associated with the develop- 
ment of ventricular fibrillation during the post 
hospital phase of myocardial infarction have 
enhanced our ability to identify groups of patients at 
high risk for the development of sudden coronary 
death.23, 24 The identification of efficacious antifibril- 
latory compounds such as bretylium tosylate 
through the use of appropriate animal models may 
help identify effective pharmacologic interventions 
capable of reducing mortality in these high risk 
patients. The antifibrillatory actions of bretylium 
tosylate make this drug a serious candidate for 
continued study in humans to determine its efficacy 
in reducing the risk for sudden coronary death. 
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Failure of bretylium to suppress inducible 
ventricular tachycardia 
Five patients with recurrent, life-threatening ventricular arrhythmias were given bretylium tosylate 
intravenously for a minimum of 4 days. Arrhythmias were not related to acute ischemla in any 
patient. Four patients had inducible ventricular tachycardia, and one patient had inducible 
ventricular fibrillation requiring cardloversion while taking no medications. Programmed electrical 
stimulation was then repeated to assess the ability of bretyllum to suppress Inducible ventricular 
tachycardia. Bretylium tosylate, at a mean dose of 2.3 mg intravenously per minute, did not 
suppress inducible ventricular arrhythmias In any patient. Rapid ventricular tachycardia was 
induced in all patients, and ventricular fibrillation was induced In one patient. Two patients 
required external cardloversion to terminate their arrhythmias. Bretylium tosylate, given in 
relatively large doses chronlcally, did not suppress inducible ventricular arrhythmias In these five 
otherwise drug-refractory patients with chronic recurrent ventricular tachycardia. This failure to 
suppress inducible ventricular arrhythmias cannot be attributed to the initial catecholamlne 
release which occurs in the first hour or two after the drug is administered, (AM HEART J K&717, 
1983.) 
H. Leon Greene, M.D., Jeffrey A. Werner, M.D., Brian W. Gross, M.D., and 
Gena K. Sears, R.N. Seattle, Wash. 
Bretylium tosylate is an antiarrhythmic drug which 
can be categorized as a Vaughan-Williams type HI 
agent.’ It increases the ventricular fibrillation 
threshold2 and prolongs action potential duration 
and the effective refractory period without much 
effect on the rate of rise of the cardiac action 
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potential.3 Bretylium is indicated for treatment of 
ventricular fibrillation, prophylaxis against ventric- 
ular fibrillation, or treatment of ventricular tachy- 
cardia after failure of a first-line drug. 
Intracardiac electrophysiologic studies are rou- 
tinely performed to assist in the choice of antiar- 
rhythmic therapy for patients with ventricular dys- 
rhythmias.4-6 The ability of an antiarrhythmic agent 
to suppress arrhythmia induction with these tech- 
niques is predictive of long-term success of that 
agent. However, certain drugs, while remaining 
effective clinically, do not suppress inducible ven- 
tricular arrhythmias.‘-* Amiodarone, also a type III 
drug, is useful clinically and suppresses spontaneous 
717 
